We are live on ! Find out more
GFM

GF Fund Management Portfolio holdings

AUM $8.34B
1-Year Est. Return 165.53%
This Fund
S&P 500
This Quarter Est. Return
+77.9%
1 Year Est. Return
+165.53%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$8.34B
AUM Growth
+$2.35B
Cap. Flow
-$42M
Cap. Flow %
-0.5%
Top 10 Hldgs %
46.57%
Holding
644
New
20
Increased
132
Reduced
424
Closed
57

Top Buys

Rank Stock Value
1
INIO
INNIO N.V.
INIO
+$177M
2
AMD icon
Advanced Micro Devices
AMD
+$119M
3
FORM icon
FormFactor
FORM
+$101M
4
CBRS
Cerebras Systems
CBRS
+$70.1M
5
ONTO icon
Onto Innovation
ONTO
+$64.5M

Top Sells

Rank Stock Value
1
TSEM icon
Tower Semiconductor
TSEM
+$220M
2
LITE icon
Lumentum
LITE
+$219M
3
TSLA icon
Tesla
TSLA
+$50.1M
4
CIEN icon
Ciena
CIEN
+$43.3M
5
MSFT icon
Microsoft
MSFT
+$42.6M

Sector Composition

Rank Sector Weight
1 Technology 66.11%
2 Communication Services 9.64%
3 Consumer Discretionary 8.42%
4 Industrials 4.35%
5 Healthcare 4.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CME icon
401
CME Group
CME
$101B
$44.2K ﹤0.01%
+200
New +$55.3K
LXP icon
402
LXP Industrial Trust
LXP
$3.58B
$43.3K ﹤0.01%
803
-92
-10% -$4.74K
PGEN icon
403
Precigen
PGEN
$2.54B
$42.7K ﹤0.01%
7,487
-427
-5% -$1.85K
NSA
404
DELISTED
National Storage Affiliates Trust
NSA
$42.3K ﹤0.01%
952
-152
-14% -$6.51K
NTLA icon
405
Intellia Therapeutics
NTLA
$1.79B
$42.3K ﹤0.01%
2,502
-85
-3% -$1.19K
ADMA icon
406
ADMA Biologics
ADMA
$2.15B
$42.2K ﹤0.01%
5,041
-305
-6% -$2.78K
RAPP
407
Rapport Therapeutics
RAPP
$2.2B
$42.1K ﹤0.01%
1,011
-59
-6% -$2.17K
AMLX icon
408
Amylyx Pharmaceuticals
AMLX
$3.8B
$41.8K ﹤0.01%
2,326
-129
-5% -$2K
SION
409
Sionna Therapeutics
SION
$325M
$41.6K ﹤0.01%
946
-57
-6% -$2.28K
ZYME icon
410
Zymeworks
ZYME
$2.09B
$41.4K ﹤0.01%
1,585
-96
-6% -$2.44K
SNDX icon
411
Syndax Pharmaceuticals
SNDX
$1.84B
$40.8K ﹤0.01%
1,868
-84
-4% -$1.75K
RXRX icon
412
Recursion Pharmaceuticals
RXRX
$1.95B
$40.5K ﹤0.01%
11,043
-463
-4% -$1.54K
ATAI icon
413
AtaiBeckley Inc
ATAI
$2.74B
$40.5K ﹤0.01%
7,685
-440
-5% -$1.85K
BCAX
414
Bicara Therapeutics
BCAX
$1.53B
$39.9K ﹤0.01%
1,343
+123
+10% +$2.75K
SRPT icon
415
Sarepta Therapeutics
SRPT
$2.38B
$39.8K ﹤0.01%
2,217
-126
-5% -$2.38K
STOK icon
416
Stoke Therapeutics
STOK
$1.92B
$39.7K ﹤0.01%
1,212
-71
-6% -$2.28K
ANIP icon
417
ANI Pharmaceuticals
ANIP
$1.64B
$39.5K ﹤0.01%
477
-27
-5% -$2.17K
TSHA icon
418
Taysha Gene Therapies
TSHA
$1.82B
$39.5K ﹤0.01%
5,797
-331
-5% -$1.96K
GLUE icon
419
Monte Rosa Therapeutics
GLUE
$1.18B
$39.1K ﹤0.01%
1,616
+163
+11% +$3.08K
LINE
420
Lineage Inc
LINE
$8.69B
$39.1K ﹤0.01%
903
-135
-13% -$5.31K
UE icon
421
Urban Edge Properties
UE
$2.65B
$39K ﹤0.01%
1,704
-199
-10% -$4.39K
ANAB icon
422
AnaptysBio
ANAB
$1.68B
$38.9K ﹤0.01%
576
-45
-7% -$2.73K
PK icon
423
Park Hotels & Resorts
PK
$3.07B
$38.3K ﹤0.01%
2,686
-336
-11% -$4.11K
CURB
424
Curbline Properties
CURB
$3.39B
$37.8K ﹤0.01%
1,244
-188
-13% -$5.37K
GMAB icon
425
Genmab
GMAB
$20.7B
$37.5K ﹤0.01%
1,364
+51
+4% +$1.35K
15 16
17
18 19

Similar funds

GLF
Groupe la Francaise Paris, France $8.31B AUM 37.53% 1-Year Est. Return
PS
Principal Securities Des Moines, Iowa $8.31B AUM 21.94% 1-Year Est. Return
CFG
Citizens Financial Group Providence, Rhode Island $8.3B AUM 27.66% 1-Year Est. Return
MAM
Madison Asset Management Madison, Wisconsin $8.39B AUM 16.36% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
MWM
Modern Wealth Management Lenexa, Kansas $8.4B AUM 21.02% 1-Year Est. Return
HCM
Howard Capital Management Roswell, Georgia $8.4B AUM 51.89% 1-Year Est. Return
OCA
OpenArc Corporate Advisory Atlanta, Georgia $8.41B AUM

GF Fund Management's Q2 2026 Portfolio in Review

As of Q2 2026, GF Fund Management held 644 positions worth $8.34B, up 39% from $5.98B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

GF Fund Management's Q2 2026 filing shows 20 new, 132 increased, 424 reduced and 57 closed positions. Its largest new stake was INNIO N.V.: 4,970,000 shares worth $197M. The largest sale was Tower Semiconductor, an estimated $220M.

By sector, the portfolio is most concentrated in Technology at 66% of assets, up from 54% a quarter earlier, followed by Communication Services and Consumer Discretionary.

  • GF Fund Management's largest Q2 2026 buy was INNIO N.V.: 4,970,000 shares worth $197M.
  • GF Fund Management added most to Advanced Micro Devices in Q2 2026, an estimated $119M increase.
  • GF Fund Management's biggest Q2 2026 reduction was Tower Semiconductor, cutting an estimated $220M.
  • GF Fund Management fully exited Coherent in Q2 2026, selling an estimated $23.3M.
  • GF Fund Management's ten largest holdings make up 47% of its $8.34B portfolio in Q2 2026.
  • GF Fund Management opened 20 new positions and closed 57 in Q2 2026.
  • GF Fund Management's portfolio value rose 39% quarter-over-quarter to $8.34B.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.